Premerger rules change: Preserving competition or burdening biopharma?
This article was originally published in Scrip
Executive Summary
Many more licensing agreements among drug makers could come under US antitrust review – about 30 more transactions per year – if a newly proposed change in the reporting rules is adopted, which could mean added scrutiny, fees potentially up to $280,000, an additional waiting period to seal a deal and more paperwork for biopharma firms.